Immunotherapy for type 1 diabetes

Abstract

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder in which the immune system attacks insulin-producing β cells in the pancreas, leading to insulin deficiency and hyperglycemia. Despite advancements in treatment, managing T1D remains challenging, with patients experiencing diabetes distress and reduced life expectancy. Immunotherapy offers promising strategies for modifying the course of T1D by targeting the immune system’s attack on β cells. A recent highlight is teplizumab, an anti-CD3 monoclonal antibody, which delays the progression of T1D in patients with recent onset by preserving endogenous insulin production. Clinical trials have shown that teplizumab can improve glycemic control and delay the onset of stage 3 T1D for up to two years in at-risk individuals. Other immunotherapies, including targeting B cells with rituximab, have shown potential to preserve β cell function and reduce insulin requirements in recent-onset T1D. Additionally, T cell modulation therapies such as abatacept have been shown to slow the decline in β cell function. Cytokine-directed therapies targeting inflammation have also demonstrated potential in preserving β cell function and improving glycemic control. Combination therapies, such as the use of anti-interleukin (IL)-21 antibodies with liraglutide, may offer synergistic benefits and preserve endogenous insulin secretion. While immunotherapies offer the potential for short-term protection of β cells, ongoing research is needed to refine treatment strategies and identify optimal timing and combinations of therapies. This could lead to safer and more effective management of T1D, potentially reducing reliance on insulin therapy and providing long-term benefits for patients.

Keywords

Type 1 diabetes / immunology / immunotherapy / teplizumab / pancreatic β cells

References

[1] Secrest AM, Washington RE, Orchard TJ. Mortality in Type 1 Diabetes. In: Cowie CC, Casagrande SS, Menke A, et al, editors. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018. CHAPTER 35.

[2] Zhang X,Liu D,Xu J.Antigen-specific immunotherapies in type 1 diabetes.J Trace Elem Med Biol2022;73:127040

[3] Milluzzo A,Brozzetti A.Risk for coexistent autoimmune diseases in familial and sporadic type 1 diabetes is related to age at diabetes onset.Endocr Pract2021;27:110-7

[4] Jacobsen LM,Perry DJ,Haller MJ.Immune mechanisms and pathways targeted in type 1 diabetes.Curr Diab Rep2018;18:90 PMCID:PMC8053389

[5] Li SJ,Chen JH,Duan J.Autoimmune diseases: targets, biology, and drug discovery.Acta Pharmacol Sin2024;45:674-85 PMCID:PMC10943205

[6] Zullo A,Nicoletti G,Mancini FP.Epigenetics and type 1 diabetes: mechanisms and translational applications.Transl Res2017;185:85-93

[7] Waernbaum I.Low mean temperature rather than few sunshine hours are associated with an increased incidence of type 1 diabetes in children.Eur J Epidemiol2016;31:61-5

[8] Kostopoulou E,Skiadopoulos S.Seasonal variation and epidemiological parameters in children from Greece with type 1 diabetes mellitus (T1DM).Pediatr Res2021;89:574-8

[9] Ahadi M,Moazzami K.Association between environmental factors and risk of type 1 diabetes - a case-control study.Endokrynol Pol2011;62:134-7

[10] Rewers M.Environmental risk factors for type 1 diabetes.Lancet2016;387:2340-8 PMCID:PMC5571740

[11] Wang K,Chen Y.Association between enterovirus infection and type 1 diabetes risk: a meta-analysis of 38 case-control studies.Front Endocrinol (Lausanne)2021;12:706964 PMCID:PMC8453141

[12] Aarnisalo J,Vainionpää R,Knip M.Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes.Diabetologia2008;51:769-72

[13] Nishiumi T,Inamoto S.Case of fulminant type 1 diabetes mellitus associated with parvovirus B19 infection.J Diabetes Investig2014;5:472-3 PMCID:PMC4210061

[14] Levet S,Joanou J.An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes.JCI Insight2017;2:94387 PMCID:PMC5621895

[15] Butalia S,Khokhar B.Environmental risk factors and type 1 diabetes: past, present, and future.Can J Diabetes2016;40:586-93

[16] Rubino F,Zimmet P.New-onset diabetes in covid-19.N Engl J Med2020;383:789-90 PMCID:PMC7304415

[17] Suwanwongse K.Newly diagnosed diabetes mellitus, DKA, and COVID-19: causality or coincidence?.J Med Virol2021;93:1150-3 PMCID:PMC7404645

[18] Zhou H,Sun L.Gut microbiota profile in patients with type 1 diabetes based on 16S rRNA gene sequencing: a systematic review.Dis Markers2020;2020:3936247 PMCID:PMC7474751

[19] Vaarala O,Neu J.The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity.Diabetes2008;57:2555-62 PMCID:PMC2551660

[20] Abuqwider J,Scidà G.Gut microbiome and blood glucose control in type 1 diabetes: a systematic review.Front Endocrinol (Lausanne)2023;14:1265696 PMCID:PMC10684760

[21] Chierico F, Rapini N, Deodati A, Matteoli MC, Cianfarani S, Putignani L. Pathophysiology of type 1 diabetes and gut microbiota role.Int J Mol Sci2022;23:14650 PMCID:PMC9737253

[22] Meng X,Keane ST,Durham SR.Immunological mechanisms of tolerance: central, peripheral and the role of T and B cells.Asia Pac Allergy2023;13:175-86 PMCID:PMC10715743

[23] Unger WW,Abreu JR.Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.PLoS One2012;7:e49213 PMCID:PMC3498321

[24] Bluestone JA,Eisenbarth G.Genetics, pathogenesis and clinical interventions in type 1 diabetes.Nature2010;464:1293-300 PMCID:PMC4959889

[25] Atkinson MA,Eisenbarth GS.How does type 1 diabetes develop?.Diabetes2011;60:1370-9 PMCID:PMC3292309

[26] Lennon GP,Burton AR.T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.Immunity2009;31:643-53 PMCID:PMC2763021

[27] Skowera A,McLaren JE.β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.Diabetes2015;64:916-25 PMCID:PMC4557541

[28] Greeley SA,Yu L.Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.Nat Med2002;8:399-402

[29] Vehik K, Bonifacio E, Lernmark Å, et al; TEDDY Study Group. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study. Diabetes Care 2020;43:2066-73. PMCID:PMC7440899

[30] Mathieu C.Arresting type 1 diabetes: are we there yet?.Metab Target Organ Damage2022;2:15

[31] Maddaloni E,Frier BM.C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective.Diabetes Obes Metab2022;24:1912-26 PMCID:PMC9543865

[32] Weykamp C.HbA1c: a review of analytical and clinical aspects.Ann Lab Med2013;33:393-400 PMCID:PMC3819436

[33] Pociot F.Capturing residual beta cell function in type 1 diabetes.Diabetologia2019;62:28-32

[34] Nakayama M.Using the T cell receptor as a biomarker in type 1 diabetes.Front Immunol2021;12:777788 PMCID:PMC8635517

[35] Moulder R, Välikangas T, Hirvonen MK, et al; INNODIA consortium. Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory. Diabetologia 2023;66:1983-96. PMCID:PMC10542287

[36] Maddipati KR.Characterization of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidase.J Biol Chem1987;262:17398-403.

[37] Zhang N,Lin Z.Insights into the role of glutathione peroxidase 3 in non-neoplastic diseases.Biomolecules2024;14:689 PMCID:PMC11202029

[38] Insel RA,Atkinson MA.Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association.Diabetes Care2015;38:1964-74 PMCID:PMC5321245

[39] Sims EK, Besser REJ, Dayan C, et al; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 2022;71:610-23. PMCID:PMC9114719

[40] Feutren G,Assan R.Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.Lancet1986;2:119-24

[41] Masharani UB.Teplizumab therapy for type 1 diabetes.Expert Opin Biol Ther2010;10:459-65 PMCID:PMC2825571

[42] Smith JA,Clark MR,Bluestone JA.Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.J Exp Med1997;185:1413-22 PMCID:PMC2196281

[43] Herold KC,Gottlieb PA,Raymond R.Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function.Diabetes Care2023;46:1848-56 PMCID:PMC10545553

[44] Herold KC,Auger JA.Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.N Engl J Med2002;346:1692-8

[45] Herold KC,Ehlers MR.AbATE Study TeamTeplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.Diabetes2013;62:3766-74 PMCID:PMC3806618

[46] Sherry N,Ludvigsson J.Protégé Trial InvestigatorsTeplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.Lancet2011;378:487-97 PMCID:PMC3191495

[47] Herold KC,Alice Long S.An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.N Engl J Med2020;382:586

[48] Ramos EL, Dayan CM, Chatenoud L, et al; PROTECT Study Investigators. Teplizumab and β-Cell function in newly diagnosed type 1 diabetes.N Engl J Med 2023;389:2151-61.

[49] Aronson R, Gottlieb PA, Christiansen JS, et al; DEFEND Investigator Group. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014;37:2746-54. PMCID:PMC4392937

[50] Ambery P,Biswas N,Parkin J.Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.Diabet Med2014;31:399-402

[51] Keymeulen B,Inman D.A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.Diabetologia2021;64:313-24 PMCID:PMC7801303

[52] Siddiqui S,Herzig R,Hildebrandt GC.Anti-thymocyte globulin in haematology: recent developments.Indian J Med Res2019;150:221-7 PMCID:PMC6886146

[53] Simon G,Ramiya V.Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation.Diabetes2008;57:405-14

[54] Gitelman SE, Gottlieb PA, Rigby MR, et al; START Study Team. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013;1:306-16. PMCID:PMC6489466

[55] Haller MJ, Long SA, Blanchfield JL, et al; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA_1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes 2019;68:1267-76. PMCID:PMC6610026

[56] Foster TP,Bruggeman B.Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes.Diabetes Care2024;47:285-9 PMCID:PMC10834389

[57] Pescovitz MD.The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.Pediatr Transplant2004;8:9-21

[58] Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al; Type 1 diabetes Trialnet anti-CD20 study group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52. PMCID:PMC6410357

[59] Pescovitz MD, Greenbaum CJ, Bundy B, et al; Type 1 Diabetes TrialNet anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 2014;37:453-9. PMCID:PMC3898764

[60] Viglietta V.Modulating co-stimulation.Neurotherapeutics2007;4:666-75 PMCID:PMC7479684

[61] Korhonen R.Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.Basic Clin Pharmacol Toxicol2009;104:276-84

[62] Herrero-Beaumont G,Castañeda S.Abatacept mechanism of action: concordance with its clinical profile.Reumatol Clin2012;8:78-83

[63] Orban T, Bundy B, Becker DJ, et al; Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014;37:1069-75. PMCID:PMC3964491

[64] Russell WE, Bundy BN, Anderson MS, et al; Type 1 Diabetes TrialNet Study Group. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care 2023;46:1005-13. PMCID:PMC10154649

[65] Chamian F,Lee E.Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.J Transl Med2007;5:27 PMCID:PMC1906741

[66] Chaarani J.Alefacept: where it stands today.Expert Opin Drug Metab Toxicol2010;6:355-61

[67] Rigby MR, DiMeglio LA, Rendell MS, et al; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284-94. PMCID:PMC3957186

[68] Diggins KE,Muir V.Exhausted-like CD8⁺ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.JCI Insight2021;6:142680 PMCID:PMC7934874

[69] Lu J,Li L,Liang Y.Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets.Clin Transl Immunology2020;9:e1122 PMCID:PMC7074462

[70] Mastrandrea L,Behrens T.Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.Diabetes Care2009;32:1244-9

[71] Quattrin T, Haller MJ, Steck AK, et al; T1GER Study Investigators. Golimumab and Beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 2020;383:2007-17.

[72] Huang IH,Wu PC.JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review.Front Immunol2022;13:1068260 PMCID:PMC9773077

[73] Benucci M,Coccia C.JAK inhibitors and autoimmune rheumatic diseases.Autoimmun Rev2023;22:103276

[74] Waibel M, Wentworth JM, So M, et al; BANDIT Study Group. Baricitinib and β-cell function in patients with new-onset type 1 diabetes. N Engl J Med 2023;389:2140-50.

[75] Nagy S,Hussein A.The development of diabetes and diabetic ketoacidosis following immunotherapy treatment: a systematic review of case reports.Cureus2024;16:e57894 PMCID:PMC11007471

[76] Nepal D.Phase 2 trial of peresolimab for adults with rheumatoid arthritis.N Engl J Med2023;389:378-9

[77] Long D,Wu H,Lu Q.Clinical significance and immunobiology of IL-21 in autoimmunity.J Autoimmun2019;99:1-14

[78] Rydén AK,Pagni PP.Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.J Autoimmun2017;84:65-74

[79] Herrath M, Bain SC, Bode B, et al; Anti-IL-21–liraglutide Study Group investigators and contributors. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9:212-24.

[80] Coppieters K.Antigen-specific peptide immunotherapy for type 1 diabetes: proof of safety, hope for efficacy.Cell Metab2017;26:595-7

[81] Steck AK, Fouts A, Miao D, et al; TrialNet Study Group. ECL-IAA and ECL-GADA can identify high-risk single autoantibodypositive relatives in the TrialNet pathway to prevention study. Diabetes Technol Ther 2016;18:410-4. PMCID:PMC4931768

[82] Ziegler AG,Schenker M.Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.Diabetes1999;48:460-8

[83] Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus.N Engl J Med2002;346:1685-91

[84] Skyler JS,Wolfsdorf J.Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial--type 1.Diabetes Care2005;28:1068-76

[85] Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ; Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 2017;318:1891-902. PMCID:PMC5798455

[86] Ludvigsson J,Casas R.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.N Engl J Med2012;366:433-42

[87] Tavira B,Axelsson S,Ludvigsson J.Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD₆₅-induced immune response.Diabetologia2017;60:1276-83 PMCID:PMC5487599

[88] Casas R,Puente-Marin S.Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE extension trial).Acta Diabetol2022;59:687-96 PMCID:PMC8995247

[89] Hannelius U,Ludvigsson J.Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.Diabetologia2020;63:2177-81 PMCID:PMC7476912

[90] Roep BO, Solvason N, Gottlieb PA, et al; BHT-3021 Investigators. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabete. Sci Transl Med 2013;5:191ra8. PMCID:PMC4516024

[91] Bender C,Amirian N,von Herrath MG.The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes.Sci Adv2020;6:eabc5586 PMCID:PMC7567597

[92] Anderson AM,Alkanani AA.Human islet T cells are highly reactive to preproinsulin in type 1 diabetes.Proc Natl Acad Sci U S A2021;118:e2107208118 PMCID:PMC8521679

[93] Lin C,Cai X.The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: a systematic review and meta-analysis.Pharmacol Res2024;203:107157

[94] Purcell AW,DiLorenzo TP.The evolving landscape of autoantigen discovery and characterization in type 1 diabetes.Diabetes2019;68:879-86 PMCID:PMC6477901

[95] Wilcox NS,Hebrok M.Life and death of β cells in type 1 diabetes: a comprehensive review.J Autoimmun2016;71:51-8 PMCID:PMC4903951

[96] Sims EK, Bundy BN, Stier K, et al; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individual. Sci Transl Med 2021;13:eabc8980. PMCID:PMC8610022

[97] Felton JL.Timing of Immunotherapy in type 1 diabetes: the earlier, the better?.Immunohorizons2021;5:535-42